[Small intestinal absorption during cyclophosphamide therapy assessed by vitamin B 12 and d-xylose tolerance tests].
D000328:Adult; D000367:Age Factors; D000368:Aged; D003520:Cyclophosphamide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007408:Intestinal Absorption / Q000187:drug effects*; D007421:Intestine, Small / Q000378:metabolism; D007437:Intrinsic Factor / Q000378:metabolism; D008175:Lung Neoplasms / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012737:Sex Factors; D013274:Stomach Neoplasms / Q000188:drug therapy; D014805:Vitamin B 12; D014994:Xylose
D003520:Cyclophosphamide; D007437:Intrinsic Factor; D014994:Xylose; D014805:Vitamin B 12
Tyndtarmsabsorptionen ved cyklofosfamid behandling. Bedømt ved B 12-vitamin- og d-xylosebelastning.